Post date
24/06/2025
Novadip is developing NVD003, an autologous therapy derived from adipose stem cells, as a potential single treatment to save limbs and restore mobility in patients with CPT.
The RMAT designation is part of the IND that Novadip obtained for NVD003, with plans to reach the US market in 2027.
More information on the website of Novadip: https://novadip.com/press-releases/novadip-receives-rmat-designation-for-nvd003its-regenerative-treatment-for-congenital-pseudarthosis-of-the-tibia/